In a report released yesterday, Hartaj Singh from Oppenheimer maintained a Buy rating on NeuBase Therapeutics (NBSE – Research Report), with a price target of $17.00. The company’s shares closed last Wednesday at $9.07.
According to TipRanks.com, Singh is a 5-star analyst with an average return of 16.8% and a 47.9% success rate. Singh covers the Healthcare sector, focusing on stocks such as Catabasis Pharmaceuticals, Alexion Pharmaceuticals, and Vertex Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for NeuBase Therapeutics with a $17.00 average price target.
The company has a one-year high of $11.78 and a one-year low of $4.52. Currently, NeuBase Therapeutics has an average volume of 181.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
NeuBase Therapeutics, Inc. engages in the development of drugs for patients with genetic neurological disorder. Its pipelines include Huntington’s Disease, NT0100 Program – PATrOL Enabled gamma-PNA for Huntington’s Disease, and NT0200 Program- PATrOL Enabled gamma-PNA for Myotonic Dystophy. The company was founded by Dietrich A. Stephan on August 28, 2018 and is headquartered in Pittsburgh, PA.